Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Date:8/8/2013

have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer.  Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial completion and design, statements regarding the potential benefits and potential development of our product candidates and statements regarding our future expenses and the use and adequacy of our cash resources. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that our product candidates will not demonstrate the hypothesized or expected benefits, the risk of delays in our expected clinical trials, the risk that new developments in the rapidly evolving cancer therapy landscape require changes in our clinical trial plans or limit the potential benefits of our product candidates and the other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including the Company's Annual Rep
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
3. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
4. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
5. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
6. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
7. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
8. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
9. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
10. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
11. Auxilium Pharmaceuticals, Inc, Announces Second Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... -- Market research firm Kalorama information says that 2014 will ... the medical device industry.  The firm thinks the $360 ... 3% growth this year, which led firms to look ... and entrance by acquisition into new competitive zones.  The ... The Global Market for Medical Devices, 5 th ...
(Date:11/21/2014)... , 21. November 2014 Michael ... sich am Morgen des 14. Februar 2014 zugetragen hat. ... wohl kaum vergessen. Video - http://youtu.be/5cVoMCe0uiE ... ich dabei war, mein morgendliches Training zu machen", erzählt ... zu der Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. ...
(Date:11/21/2014)...  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ) ... public offering of $50,000,000 of shares of its common ... offering will consist of 49,751,244 shares of common stock ...  Lexicon has also granted the underwriters a 30-day option ... stock.  All of the shares in the offering will ...
Breaking Medicine Technology:Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3
... Japan, April 15, 2011 Takeda Pharmaceutical Company Limited ... today announced that EDARBI (azilsartan medoxomil), an angiotensin II ... or high blood pressure, is now available by prescription ... Drug Administration (FDA) approved EDARBI on February 25, 2011 ...
... 2011 Theramed Corporation ("Theramed") announces that it ... for the EBB® Complete Tamponade System and the ... devices used to advance the practice of obstetrics, ... medical device products have been approved for sale ...
Cached Medicine Technology:EDARBI (azilsartan medoxomil), Now Available in U.S. Pharmacies for Patients With Hypertension 2EDARBI (azilsartan medoxomil), Now Available in U.S. Pharmacies for Patients With Hypertension 3EDARBI (azilsartan medoxomil), Now Available in U.S. Pharmacies for Patients With Hypertension 4EDARBI (azilsartan medoxomil), Now Available in U.S. Pharmacies for Patients With Hypertension 5Theramed Secures Exclusive Canadian Distribution Rights for Two Novel Obstetrics Products from Glenveigh 2
(Date:11/23/2014)... AngelWeddingDress.com has recently updated its online store, offering ... “If you are looking for gorgeous beach wedding dresses ... Here you can enjoy 70% off discounts and all ... big marriage ceremony is the most important dream of ... is uppermost priority. Ophelia, one of customers, said, “I ...
(Date:11/23/2014)... Wright & Schulte LLC recently filed 40 C8 ... residents who allege that they developed thyroid disease, high ... C8 contaminated water released by the DuPont Washington ... C8 complaints, the plaintiffs were exposed to the C8 ... least one of the six water districts affected by ...
(Date:11/22/2014)... Cancer researchers in New York and Minnesota believe ... and the growth and spread of mesothelioma. Click ... Surviving Mesothelioma website. , Doctors at Memorial Sloan ... just released their study on tunneling nanotubes (TnTs), actin-based ... found that mesothelioma cells contain many more ...
(Date:11/22/2014)... BambooFlooringChina.com is a famous brand in the bamboo ... collection of bamboo mats ; the new models are ... , According to the sales manager of BambooFlooringChina.com, Bamboo ... highly renewable resource. Their bamboo mats are 100% made from ... from natural bamboo with caramel bamboo strips. , ...
(Date:11/22/2014)... 22, 2014 In order to provide better ... of cocktail party dresses. The business knows that a suitable ... occasions. , Now, the party dresses supplier’s high ... off. As the leading company in fashion industry, LunaDress understands ... for every customer. So it always raises the professional level ...
Breaking Medicine News(10 mins):Health News:Beach Wedding Dresses Added to Outstanding Online Dress Company AngelWeddingDress.com 2Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 2Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 3Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 4Health News:Study Links Cellular ‘Tunnels’ to Mesothelioma Proliferation, According to Surviving Mesothelioma 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2
... of Oregon Health & Science University, received a research ... (NTI) to study a method that could more accurately ... ill or obese trauma patients. Schreiber,s study is ... NTI, a nonprofit organization dedicated to funding trauma research ...
... (ESMO), the leading professional organization for medical oncology ... been included among the medical specialties covered by ... as announced yesterday by the Commission. The decision ... between ESMO, key national societies and EU Member ...
... radiation inside a tumour using,boron-10 and thermal neutrons. Boron-10 ... a special carrier substance (phenylalanine), after which the tumour ... the boron to generate high-LET radiation, which may destroy ... may be sufficient to destroy a tumour, while keeping ...
... , FRIDAY, March 4 (HealthDay News) -- ... they have good parks and playgrounds in their neighborhoods, ... of 171 nine-year-old children to give their opinions about ... the amount of time their children spent watching television, ...
... (HealthDay News) -- An analysis of breast tissue may help ... new study reports. Researchers analyzed what they describe as ... that the way collagen fibers -- the main component of ... diagnosis and help determine treatment. Collagen not only surrounds ...
... (ASM) will hold its 111th General Meeting May ... meeting will feature approximately 3,000 individual scientific presentations ... expected attendance of 10,000. Microbiologists study living ... critical to human and animal health, agriculture, the ...
Cached Medicine News:Health News:BNCT, a new-generation radiation treatment, is effective in advanced head and neck cancer 2Health News:Tissue Analysis May Help Predict Breast Cancer Outcome 2Health News:American Society for Microbiology to host 111th General Meeting in New Orleans 2
... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... A fixed pipette is ideal ... single volume. Fixed volume FInnpipettes ... advantages as other Finnpipette Digital ... Super blow-out (1-40ul), Soft-touch tip ...
Medicine Products: